Stead Impact Ventures

What Stead Impact Ventures does

Stead Impact Ventures is a privately held family office and impact investment firm founded in 2023 by the Stead family — Jerre Stead, Mary Joy Stead, Jay Stead, and Joel Stead — operating as the venture capital arm complementing the Stead Foundation's philanthropic giving (the Foundation has granted over $400 million to healthcare, education, and faith-based organizations since the 1990s). The firm invests with purpose in early-stage companies whose technologies aim to bend the curve of neurodegenerative disorders (Alzheimer's disease, ALS, Fragile X Syndrome), mental health, and metabolic health. Its investment portfolio includes diagnostic platforms (ALZpath's pTau217 antibody for Alzheimer's blood testing, Amydis's ocular tracers), therapeutic developers (Spinogenix's synaptic regenerative compounds SPG601, SPG302, and Tazbentetol), digital health applications (elbi's dementia caregiver app, Inseer's computer-vision workplace safety platform, Darroch Medical Solutions' patient monitoring), metabolic health platforms (MedWatch Technologies' needle-free glucose biosensor with AI coaching), and adjacent investments (Cato in medical supply chain, AccuTitle in real estate technology). The firm operates the Stead Innovators Network to deliver mentorship, strategic partnerships between for-profit portfolio companies and nonprofit partners, and best-practice training, alongside annual Stead Innovators Symposiums (inaugural 2024, second 2025). The portfolio is supported by a leadership team that includes CEO Tiffani Shaw (former Clarivate chief of staff and University of Iowa Center for Advancement COO overseeing $2B in operations), CMO Dana Larson, CCO Aidan Thompson (PhD in Neuroscience and Biomechanics), and Senior Advisor Sandy Rosenberg (former Citigroup investment banking, Discus Ventures founder).

Revenue mechanics are characteristic of a single-family office: Stead Impact Ventures does not charge management fees or carry, and is funded entirely by the Stead family's own capital (more than $455 million in cumulative investment across venture and grants, per the 2024 Impact Report). Returns flow from equity appreciation in portfolio companies — exemplified by the late-2021 Boston Scientific acquisition of Farapulse (a Stead-mentored portfolio company whose Pulsed Field Ablation system subsequently received FDA approval in 2024 and treated over 40,000 European patients) — and these returns reportedly fuel foundation contributions, creating a stated perpetual cycle between profitability and philanthropy. Portfolio commercial validation is led by ALZpath, whose pTau217 antibody has been licensed to Roche, Beckman Coulter, Siemens Healthineers, Bio-Techne, Quanterix, and Alamar Biosciences (collectively representing approximately half of expected pTau217-based diagnostic platforms), with Roche and Beckman Coulter receiving FDA Breakthrough Device designation. Spinogenix has secured FDA Orphan Disease designation in ALS and Fragile X Syndrome, Fast Track designation for FXS, FDA-cleared Expanded Access Program for ALS (200 patients), and FDA agreement on a Fragile X Syndrome clinical development plan. The firm's headquarters is at 9375 E Shea Boulevard, Suite 100, Scottsdale, Arizona, with portfolio and foundation activities spanning 50+ countries globally.

Name

Stead Impact Ventures

Legal name

Stead Impact Ventures and Foundation

Website

https://steadimpact.com

Company type

Private

Founded year

2023

Operating status

Operating

Headcount range

1–10 employees

Short description

Stead Impact Ventures is a private family office founded in 2023 by the Stead family that invests in early-stage healthcare companies focused on neurodegenerative disorders, mental health, and metabolic health, operating alongside the Stead Foundation's philanthropic giving across healthcare, education, and faith-based causes.

Ownership category

akta.pro rank

Product category

Healthcare Venture Capital & Impact Investing

NAICS

Portfolio Management and Investment Advice (523940)

SIC

Investment Advice (6282)

akta.pro primary industry

Impact / ESG Venture Capital (FSANAAAG)

akta.pro secondary industries

Healthcare Access & Life Sciences Impact Funds (FSANAJAI), Impact Investing (Intentional, Measurable Social/Environmental Outcomes) (FSAAALAC), SDG / Thematic Sustainable Investment Funds (FSANAJAN)

Keywords

• Healthcare venture capital
• Impact investing
• Family office investments
• Philanthropic foundation grants
• Early-stage health startups

Headquarters

HQ city

Scottsdale

HQ country

United States

HQ region

North America

Offices1 record

Markets served

GTM type

B2B

Offering type

Services

Cost components

Personnel, Operations, Marketing or Sales

Revenue model

1. Venture Capital Returns: Stead Impact Ventures generates returns through equity investments in early-stage healthcare companies. Returns from investments fuel foundation contributions to nonprofits, creating a perpetual cycle between profitability and philanthropy.
2. Philanthropic Grants: The Stead Foundation provides grants to healthcare, education, and faith-based nonprofit organizations to effect measurable and lasting change. Founded by Jerre and Mary Joy Stead, the Foundation has given more than $400 million to date.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels10 records

Core offering

Stead Impact Ventures is a family office that makes equity investments in early-stage healthcare companies focused on neurodegenerative disorders, mental health, and metabolic health. The firm pairs venture capital with comprehensive portfolio support including leadership, mentorship, strategic partnerships, and go-to-market assistance. Its affiliated Stead Foundation provides grants to healthcare, education, and faith-based nonprofits, creating a perpetual cycle between profitability and philanthropy.

Product overview

Stead Impact Ventures operates as a family office and impact investment firm investing in healthcare innovators, paired with the Stead Foundation for philanthropic giving. The core investment thesis focuses on three healthcare verticals: neurodegenerative disorders (Alzheimer's, ALS), mental health, and metabolic health. The investment portfolio includes diagnostic platforms (ALZpath for Alzheimer's blood testing, Amydis for ocular biomarker detection), therapeutic development companies (Spinogenix for synaptic regenerative drugs), digital health applications (elbi dementia caregiving app, Inseer workplace safety), and health monitoring platforms (MedWatch Technologies metabolic health, Darroch Medical patient monitoring). The Stead Innovators Network provides mentorship and strategic partnership opportunities across the portfolio companies, while the Stead Foundation extends grant funding to complementary nonprofit organizations including Banner Alzheimer's Institute and Community 43. The firm also provides portfolio companies with leadership support services including technology, marketing, and commercialization assistance.

Differentiator

Problem solved

Functional benefit

Brands

• Stead Innovators Network: A network created by Stead Impact Ventures to provide mentorship opportunities, strategic partnerships between for-profit portfolio companies and nonprofit partners, and best-practice training across startup topics.

Products and services

• Stead Innovators Network Ecosystem program creating opportunities for mentorship, strategic partnerships between for-profit portfolio companies and nonprofits, and best-practice training across vital startup topics and needs.
• Stead Foundation Grants Philanthropic foundation providing grants to healthcare, education, and faith-based nonprofit organizations, having given over $400 million to effect measurable and lasting change.
• Early-Stage Healthcare Venture Capital Investments Direct equity investments in early-stage healthcare companies focused on neurodegenerative disorders, mental health, and metabolic health, paired with leadership and support services to position portfolio companies for venture-scale returns and global impact.

Quantifiable outcome

• Spinogenix completed Phase 2a trials in Alzheimer's disease showing rapid cognitive improvement, reversing disease progression
• +3 more outcomes

Named customers10 records

Segments6 records

Ideal customer profiles2 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

AI capability8 records

Feature6 records

Partnerships

31 partnerships are on record, tiered flagship, core and minor.

• RocheflagshipTechnology or Integration · 1 January 2025Roche partnered with ALZpath to power its Alzheimer's blood test using the pTau217 antibody. Roche received FDA Breakthrough Device designation for the test.
• Beckman CoulterflagshipTechnology or Integration · 1 January 2025Beckman Coulter partnered with ALZpath for Alzheimer's blood testing using pTau217. Company received FDA Breakthrough Device designation.
• ALZpathflagshipStrategic or Co-development Partner · 1 January 2020ALZpath is a Stead Impact Ventures portfolio company founded by Dr. Eric Reiman and Jerre Stead to make accurate Alzheimer disease diagnosis accessible through blood tests using the pTau217 biomarker.
• SpinogenixflagshipStrategic or Co-development Partner · 1 January 2016Spinogenix is developing first-in-class regenerative therapeutics to restore memory and motor functions in neurodegenerative and psychiatric diseases including Alzheimer's, ALS, and Fragile X Syndrome.
• AmydiscoreStrategic or Co-development PartnerAmydis is developing ocular tracers for immediate detection of degenerative and systemic diseases, enabling early diagnosis through routine eye exams.
• MedWatch TechnologiescoreStrategic or Co-development PartnerMedWatch Technologies is building a comprehensive metabolic health platform powered by a proprietary needle-free glucose sensor paired with AI-powered coaching.
• elbicoreStrategic or Co-development Partnerelbi is revolutionizing dementia care with expert-backed, person-centered guidance and innovative technology for caregivers.
• InseercoreStrategic or Co-development PartnerInseer's AI-powered ergonomics solution enables safety teams to proactively address workplace issues before injuries occur.
• CatominorStrategic or Co-development PartnerCato reimagines the medical supply chain through transformative technologies, building trust through transparency and reliability.
• Darroch Medical SolutionsminorStrategic or Co-development PartnerDarroch Medical Solutions creates better knowledge workers through its unique patient monitoring platform with intelligent alerts for at-risk patients.
• AccuTitleminorStrategic or Co-development PartnerAccuTitle provides a real-estate transaction platform focused on streamlining processes, reducing wire fraud, and enhancing security.
• Banner Alzheimer's InstituteflagshipStrategic or Co-development PartnerEstablished by the Stead Foundation, the Institute provides hope and help for Alzheimer's patients with groundbreaking research and innovative programs.
• Community 43coreStrategic or Co-development PartnerStead Foundation-established community hub offering healing space for individuals with serious mental illness through the clubhouse concept.
• Alzheimer's AssociationcoreStrategic or Co-development PartnerLeading organization to end Alzheimer's through global research, risk reduction, early detection, and quality care support.
• Fountain HousecoreStrategic or Co-development PartnerNational mental health nonprofit fighting to improve health and end social isolation for people impacted by mental illness.
• UI Health CarecoreStrategic or Co-development PartnerAcademic medical center providing life-changing care, advancing biomedical science, and training next-generation healthcare professionals.
• UI Stead Family Children's HospitalcoreStrategic or Co-development PartnerIowa's only comprehensive children's hospital ranked by U.S. News & World Report; cared for 106k patients from 49 states and 12 countries.
• Lilly Family School of Philanthropy at Indiana UniversitycoreStrategic or Co-development PartnerWorld's first school dedicated solely to the study and teaching of philanthropy.
• Tippie College of Business at University of IowacoreStrategic or Co-development PartnerBusiness education institution cultivating innovation and excellence since 1847.
• Garrett Evangelical Theological SeminarycoreStrategic or Co-development PartnerPreparing spiritually adventurous leaders for service to Church, academy, and diverse communities for over 168 years.
• Salvation ArmyminorStrategic or Co-development PartnerInternational Christian Church organization preaching the gospel and meeting human needs without discrimination.
• Interfaith AmericaminorStrategic or Co-development PartnerOrganization inspiring, equipping, and connecting leaders to unlock America's religious diversity potential.
• Lambda Chi Alpha Educational FoundationminorStrategic or Co-development PartnerFoundation sponsoring leadership training, personal development programs, and undergraduate scholarships.
• Siemens HealthineersflagshipTechnology or IntegrationSiemens Healthineers signed agreement with ALZpath to power its Alzheimer's blood test, representing half of expected pTau217-based testing platforms.
• Bio-TechnecoreTechnology or IntegrationBio-Techne licensed ALZpath's pTau217 antibody for Alzheimer's diagnostics.
• Alamar BiosciencescoreTechnology or IntegrationAlamar Biosciences partnered with ALZpath for Alzheimer's diagnostic development using pTau217.
• QuanterixcoreTechnology or IntegrationQuanterix licensed ALZpath's pTau217 antibody for Alzheimer's blood testing.
• NeurocodecoreTechnology or IntegrationNeurocode laboratory offers ALZpath's pTau217 test for clinicians to diagnose Alzheimer's disease.
• Sensable HealthcoreStrategic or Co-development PartnerStrategic collaboration where MedWatch Technologies' sensor integrates with Sensable Health's wellness platform for proactive metabolic health management.
• Dwellings NowminorStrategic or Co-development PartnerOrganization committed to providing shelter and hope. Stead Impact team built a house for the Ramirez Fuentes family in Honduras through this partnership.
• Dreams AliveminorStrategic or Co-development PartnerNonprofit dedicated to uplifting underserved communities in Nigeria through holistic health initiatives, medical camps, and empowerment programs.

Scale indicators5 records

Recent moves7 records

Expansion highlights6 records

Direct peers

• Andreessen Horowitz (a16z Bio): Major venture firm with a dedicated bio/health fund investing across therapeutics, diagnostics, and digital health. Directly comparable given similar stage and sector focus, though at materially larger scale.
• ARCH Venture Partners: One of the largest early-stage life sciences and healthcare VCs, investing in nascent companies developing novel therapeutics, diagnostics, and platform technologies. Highly comparable to Stead Impact's early-stage, science-heavy healthcare investment thesis, though ARCH operates at much larger fund scale.
• Mission BioCapital: Early-stage venture firm exclusively focused on healthcare and life sciences, investing in therapeutics, diagnostics, and platform technologies. Highly comparable to Stead Impact's healthcare-only mandate and early-stage entry.
• Omega Funds: Healthcare-dedicated investment firm focused on life sciences across therapeutics, diagnostics, and medical devices. Comparable for the healthcare-only mandate and focus on breakthrough science, though primarily growth-stage.
• RA Capital Management: Healthcare-focused investment firm investing across public and private companies in therapeutics, medical devices, and diagnostics. Comparable given healthcare concentration and deep scientific diligence approach.
• Acumen: Impact investment fund investing in early-stage companies addressing poverty across health, energy, and agriculture. Most comparable impact-mandated peer to Stead Impact's focus on healthcare impact alongside financial returns.
• Section 32: Venture fund founded by Bill Maris focused on healthcare and technology at the intersection of biology, computation, and engineering. Directly comparable as a healthcare-focused early-stage VC backing category-defining companies.
• Khosla Ventures: Venture firm making early-stage healthcare and science investments alongside technology. Comparable as an early-stage impact-oriented investor, though with broader sector focus beyond healthcare.

Broad incumbents

• Kleiner Perkins: Established venture firm with significant healthcare practice across therapeutics, digital health, and medical devices. Comparable as an investor in early-stage healthcare innovators, though with a much broader technology mandate.
• Google Ventures (GV): Large venture arm of Alphabet with significant healthcare investing across life sciences, digital health, and diagnostics. Overlapping investment themes with Stead Impact but operates at much larger scale and broader sector exposure.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks6 records

Key highlights7 records

Customer concentration

• YouTubeyoutube.com/@SteadImpactVenturesandFo-ts8zc
• LinkedInlinkedin.com/company/stead-impact-ventures-and-foundation

Revenue estimate

Valuation estimate

Number of profiles

Profiles9 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments1 record

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Stead Impact Ventures